Cardiovascular risk factors in childhood diabetes

Endocrinologist

Volumn 13, Issue 5, 2003, Pages 394-407

  Miller, Jennifer ^a   Silverstein, Janet ^b  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

^b Box 100296   (United States)

Author keywords

Cardiovascular risk; Diabetes; Dyslipidemia; Hypertension

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BILE ACID SEQUESTRANT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LISINOPRIL; LOSARTAN; NICOTINIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PIOGLITAZONE; ROSIGLITAZONE; STATINE DERIVATIVE; THIAZIDE DIURETIC AGENT; THIAZOLIDINE DERIVATIVE; TROGLITAZONE; UNCLASSIFIED DRUG;

ARTERY INTIMA PROLIFERATION; ATHEROSCLEROTIC PLAQUE; BLOOD PRESSURE MEASUREMENT; BRACHIAL ARTERY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAROTID ARTERY; CHILD GROWTH; CHILDHOOD DISEASE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DISEASE MARKER; DOPPLER ECHOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DYSLIPIDEMIA; ENDOTHELIUM; EVIDENCE BASED MEDICINE; FAMILIAL HYPERCHOLESTEROLEMIA; FAMILY HISTORY; HEART PROTECTION; HIGH RISK POPULATION; HORMONE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; INFLAMMATION; INSULIN DEPENDENT DIABETES MELLITUS; LIFESTYLE; LONGITUDINAL STUDY; METABOLIC REGULATION; MORBIDITY; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON INVASIVE MEASUREMENT; OBESITY; PATHOGENESIS; PATIENT COMPLIANCE; PLEIOTROPY; PRACTICE GUIDELINE; REFERENCE VALUE; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEXUAL MATURATION; SIDE EFFECT; STANDARD;

EID: 0141564765     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ten.0000089910.55253.d3     Document Type: Review

References (136)

1. Daniels SR. Cardiovascular disease risk factors and atherosclerosis in children and adolescents. Curr Atheroscler Rep. 2001;3:479-485.
2. Schwandt P, Giess HC, Haas GM. Global cardiovascular risk in children and their families: the Prevention Education Program (PEP), Nurnberg. Nutr Metab Cardiovasc Dis. 2001;11(suppl 5):35-39.
3. Deckelbaum RJ, Williams CL. Childhood obesity: the health issue. Obes Res. 2001;9(suppl 4):239S-243S.
4. Vanhala M, Vanhala P, Kumpusalo E, et al. Relation between obesity from childhood to adulthood and the metabolic syndrome: a population based study. BMJ. 1998;317:319.
5. Lakka HM, Laaksonen DE, Lakka TA, et al. The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. JAMA. 2002;288:2709-2716.
6. Rosenbloom AL. Increasing incidence of type 2 diabetes in children and adolescents: treatment considerations. Paediatr Drugs. 2002;4: 209-321.
7. Knowles HC. Diabetes mellitus in children and adolescence. Med Clin North Am. 1971;55:976-987.
8. Hoq S, Chen W, Srinivasan SR, et al. Childhood blood pressure predicts adult microalbuminuria in African Americans, but not in whites: the Bogalusa Heart Study. Am J Hypertens. 2002;15:1036-1041.
9. Gale EA. The rise of childhood type 1 diabetes in the 20th century. Diabetes. 2002;51:3353-3361.
10. Silink M. Childhood diabetes: a global perspective. Horm Res. 2002;57(Supp 1):1-5.
11. Lepore G, Bruttomesso D, Nosari I, et al. Glycaemic control and microvascular complications in a large cohort of Italian type 1 diabetic out-patients. Diabetes Nutr Metab. 2002;15:232-239.
12. Olsen BS, Sjolie A, Hougaard P, et al. A 6-year nationwide cohort study of glycaemic control in young people with type 1 diabetes. Risk markers for development of retinopathy, nephropathy, and neuropathy. Danish Study Group of Diabetes in Childhood. J Diabetes Complications. 2000;14:295-300.
13. White NH, Cleary PA, Dahms W, et al. Beneficial effects of intensive therapy during adolescence: outcomes after the conclusion of the Diabetes Control and Complications Trial (DCCT). J Pediatr. 2001; 139:804-812.
14. Laing SP, Swerdlow AJ, Slater SD, et al. The British Diabetic Association Cohort Study, II: cause-specific mortality in patients with insulin-treated diabetes mellitus. Diabet Med. 1999;16:466-471.
15. Tracy RE, Newman WP III, Wattigney WA, et al. Risk factors and atherosclerosis in youth autopsy findings of the Bogalusa Heart Study. Am J Med Sci. 1995;310(suppl 1):S37-S41.
16. Wissler RW. An overview of the quantitative influence of several risk factors on progression of atherosclerosis in young people in the United States. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Am J Med Sci. 1995;310(suppl 1):S29-S36.
17. Hu BF. The impact of diabetes and prediabetes on risk of cardiovascular disease and mortality. Drugs Today (Barc). 2002;38:769-775.
18. Goetz FC, Roel J, Jacobs DR Jr, et al. Declining beta cell function in type 2 diabetes: 5-year follow-up and immunologic studies of the population in Wadena, MN. Metabolism. 2002;51:144-148.
19. Ratner RE. Glycemic control in the prevention of diabetic complications. Clin Cornerstone. 2001;4:24-37.
20. Bao W, Srinivasan SR, Valdez R, et al. Longitudinal changes in cardiovascular risk from childhood to young adulthood in offspring of parents with coronary artery disease: the Bogalusa Heart Study. JAMA. 1997;278:1749-1754.
21. Huo Y, Ley K. Adhesion molecules and atherogenesis. Acta Physiol Scand. 2001;173:35-43.
22. Kado S, Nagata N. Circulating intercellular adhesion molecule-1, vascular cell adhesion molecule-1, and E-selectin in patients with type 2 diabetes. Diabetes Res Clin Pract. 1999;46:143-148.
23. Russo G, Leopold JA, Loscalzo J. Vasoactive substances: nitric oxide and endothelial dysfunction in atherosclerosis. Vascul Pharmacol. 2002;38:259-269.
24. Weinsperger NF. In defense of microvascular constriction in diabetes. Clin Hemorheol Microcirc. 2001;25:55-62.
25. Clarkson P, Celermajer DS, Donald AE, et al. Impaired vascular reactivity in insulin-dependent diabetes mellitus is related to disease duration and low density lipoprotein cholesterol levels. J Am Coll Cardiol. 1996;28:573-579.
26. Vaccaro O, Perna AF, Mancini FP, et al. Plasma homocysteine and microvascular complications in type 1 diabetes. Nutr Metab Cardiovasc Dis. 2000;10:297-304.
27. Glowinska B, Urban M, Peczynska J, et al. Elevated concentrations of homocysteine in children and adolescents with arterial hypertension accompanying type 1 diabetes. Med Sci Monit. 2001;7:1242-1249.
28. Weisbauer F, Miles JS. C-reactive protein screening for cardiovascular disease. Arch Intern Med. 2003;163:242.
29. Jialal I. Role of C-reactive protein in assessment of cardiovascular risk. Am J Cardiol. 2003;91:200-202.
30. Kang SM, Chung N, Kim JY, et al. Relation of vasodilator response of the brachial artery to inflammatory markers in patients with coronary artery disease. Echocardiography. 2002;19:661-667.
31. Hayaishi-Okano R, Yamasaki Y, Katakami N, et al. Elevated C-reactive protein associates with early-stage carotid atherosclerosis in young subjects with type 1 diabetes. Diabetes Care. 2002;25:1432-1438.
32. Fathi R, Marwick TH. Noninvasive tests of vascular function and structure: why and how to perform them. Am Heart J. 2001;141:694-703.
33. Rosenthal DN, Chin C. Brachial artery reactivity: a modified technique with applicability to children. J Am Soc Echocardiogr. 1999;12:850-852.
34. Johnstone MT, Creager SJ, Scales KM, et al. Impaired endothelium-dependent vasodilation in patients with insulin-dependent diabetes mellitus. Circulation. 1993;88:2510-2516.
35. Caballero AE, Arora S, Saouaf R, et al. Microvascular and macrovascular reactivity is reduced in subjects at risk for type 2 diabetes. Diabetes. 1999;48:1856-1862.
36. Williams SB, Cusco JA, Roddy MA, et al. Impaired nitric oxide-mediated vasodilation in patients with non-insulin-dependent diabetes mellitus. J Am Coll Cardiol. 1996;27:567-574.
37. Aggoun Y. Arterial rigidity and endothelial dysfunction in obese children. Arch Mal Coeur Vaiss. 2002;95:631-635.
38. Urbina EM, Srinivasan SR, Tang R, et al. Impact of multiple coronary risk factors on the intima-media thickness of different segments of carotid artery in healthy young adults (The Bogalusa Heart Study). Am J Cardiol. 2002;90:953-958.
39. Yavuz T, Akcay A, Omerglu RE, et al. Ultrasonic evaluation of early atherosclerosis in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab. 2002;15:1131-1136.
40. Jarisalo M, Putto-Laurila A, Jartti L, et al. Carotid artery intima-media thickness in children with type 1 diabetes. Diabetes. 2002;51:493-498.
41. Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group.Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications. Diabetes. 1999;48:383-390.
42. Bognetti E, Calori G, Meschi F, et al. Prevalence and correlations of early microvascular complications in young type 1 diabetic patients: role of puberty. J Pediatr Endocrinol Metab. 1997;10:587-592.
43. Dunger D, Ahmed L, Ong K. Growth and body composition in type 1 diabetes mellitus. Horm Res. 2002;58(suppl 1):66-71.
44. Chiarelli F, Mohn A. Angiopathy in children with diabetes. Minerva Pediatr. 2002;54:187-201.
45. Elhadd TA, Khan F, Kirk G, et al. Influence of puberty on endothelial dysfunction and oxidative stress in young patients with type 1 diabetes. Diabetes Care. 1998;21:1990-1996.
46. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy. N Engl J Med. 2000;342:381-389.
47. Kashiwagi A. Endothelial cell dysfunction diabetes mellitus-oxidative stress and cell injury. Nippon Rinsho. 2002;60(suppl 8):216-224.
48. Ceriello A, Taboga C, Tonutti L, et al. Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation. 2002;106:1211-1218.
49. Garg JP, Bakris GL. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002;7:35-43.
50. Naidoo DP. The link between microalbuminuria, endothelial dysfunction and cardiovascular disease in diabetes. Cardiovasc J S Afr. 2002; 13:194-199.
51. Maytin M, Leopold J, Loscalzo J. Oxidant stress in the vasculature. Curr Atheroscler Rep. 1999;1:156-164.
52. John S, Schmieder RE. Impaired endothelial function in arterial hypertension and hypercholesterolemia: potential mechanisms and differences. J Hypertens. 2000;18:363-374.
53. Yki-Jarvinen H. Management of type 2 diabetes mellitus and cardiovascular risk: lessons from intervention trials. Drugs. 2000;60:975-983.
54. Lea JP, Nicholas SB. Diabetes mellitus and hypertension: key risk factors for kidney disease. J Natl Med Assoc. 2002;94(8 suppl):7S-15S.
55. Epstein M. Evolving therapeutic strategies for retarding progression of diabetic nephropathy-an update for 2002. Acta Diabetol. 2002; 39(suppl 2):S4-S5.
56. Strojek K. What predisposes patients with diabetes to hypertension? Pol Arch Med Wewn. 2001;60:2040-2044.
57. Guerci B, Kearney-Schwartz A, Bohme P, et al. Endothelial dysfunction and type 2 diabetes. Part 1: physiology and methods for exploring the endothelial function. Diabetes Metab. 2001;27:425-434.
58. Ma LL, Zhao SP, Li J. Impairment effect of diabetes mellitus combined with hypertension on artery vasodilation. Hunan Yi Ke Da Xue Xue Bao. 2000;25:553-556.
59. Rocchini AP. Pediatric hypertension 2001. Curr Opin Cardiol. 2002; 17:385-389.
60. Friedman AL. Approach to the treatment of hypertension in children. Heart Dis. 2002;4:47-50.
61. Gulati S. Hypertension in children. Indian J Pediatr. 2002;69:1077-1081.
62. Berlowitz DR, Ash AS, Hickey EC, et al. Hypertension management in patients with diabetes: the need for more aggressive therapy. Diabetes Care. 2003;26:355-359.
63. Moser M. Current recommendations for treatment of hypertension-are they still valid? J Hypertens. 2002;20(suppl 1):S3-S10.
64. Adler AI, Stratton IM, Neil HA, et al. Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ. 2000; 321:412-419.
65. Bryg RJ, Graettinger WF. The Hypertension Optimal Treatment Study: what did it give us? Curr Hypertens Rep. 1999;1:337-341.
66. Sleight P. The HOPE study (Heart Outcomes Prevention Evaluation). J Renin Angiotensin Aldosterone Syst. 2000;1:18-20.
67. Lorini R, Cotellessa M, Minicucci L, et al. The adolescent with type 1 diabetes. Minerva Pediatr. 2001;53:375-380.
68. Writing Team for the Diabetes Control and Complications Trial/ Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA. 2002;287:2563-2569.
69. Orchard TJ, Forrest KY, Kuller LH, et al. Lipid and blood pressure treatment goals for type 1 diabetes: 10-year incidence data from the Pittsburgh Epidemiology of Diabetes Complications Study. Diabetes Care. 2001;24:1053-1059.
70. Muntner P, He J, Roccella EJ, et al. The impact of JNC-VI guidelines on treatment recommendations in the US population. Hypertension. 2002;39:897-902.
71. Abbott KC, Bakris GL. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002;139: 289-298.
72. Suzuki H. Evidence for the benefits of ACE inhibitors and AII antagonists in slowing progressive renal failure in diabetes. Nippon Rinsho. 2002;60(suppl 10):323-328.
73. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep. 2002;4:387-393.
74. Bicket DP. Using ACE inhibitors appropriately. Am Fam Physician. 2002;66:461-468.
75. Heinig RE. What should the role of ACE inhibitors be in the treatment of diabetes? Lessons from HOPE and MICRO-HOPE. Diabetes Obes Metab. 2002;4(suppl 1):S19-S25.
76. The EUCLID Study Group. Randomised placebo-controlled trial of lisinopril in normotensive patients with insulin-dependent diabetes and normoalbuminuria or microalbuminuria. Lancet. 1997;349:1787-1792.
77. Sica DA, Bakris GL. Type 2 diabetes: RENAAL and IDNT-the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002;4:52-57.
78. Weekers L, Krzwinski JM. Clinical study of the month. Nephroprotective role of angiotensin II receptor antagonists in type 2 diabetes: results of the IDNT and RENAAL trials. Rev Med Liege. 2001;56:723-726.
79. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic. JAMA. 2002;288:2981-2997.
80. Frohlich ED. Treating hypertension-what are we to believe? N Engl J Med. 2003;348:577-674.
81. Drummond K, Mauer M. The early natural history of nephropathy in type 1 diabetes: II. Early renal structural changes in type 1 diabetes. Diabetes. 2002;51:1580-1587.
82. Guntsche Z, Saravi FD, Reynals EA, et al. Parental hypertension and 24 h- blood pressure in children prior to diabetic nephropathy. Pediatr Nephrol. 2002;17:157-164.
83. Daniels SR. Consultation with the specialist. The diagnosis of hypertension in children: an update. Pediatr Rev. 1997;18:131-135.
84. National Heart, Lung, and Blood Institute. Update on the 1987 Task Force Report on High Blood Pressure in Children and Adolescents: a working group report from the National High Blood Pressure Education Program. Pediatrics. 1996;98:649.
85. Beaubien ER, Card CM, Card SE, et al. Accuracy of the Dinamap 1846 XT automated blood pressure monitor. J Hum Hypertens. 2002;16: 647-652.
86. Lurbe E, Redon J. Reproducibility and validity of ambulatory blood pressure monitoring in children. Am J Hypertens. 2002;15:69S-73S.
87. Sochett EB, Poon I, Balfe W, et al. Ambulatory blood pressure monitoring in insulin dependent diabetes mellitus adolescents with and without microalbuminuria. J Diabetes Complications. 1998;12:18-23.
88. The Trials of Hypertension Prevention Collaborative Research Group.Effects of weight loss and sodium reduction intervention on blood pressure and hypertension incidence in overweight people with high-normal blood pressure. The Trials of Hypertension Prevention, phase II. Arch Intern Med. 1997;157:657-667.
89. Timms N, Lowes L. Autonomy or non-compliance in adolescent diabetes? Br J Nurs. 1999;8:794-797.
90. Hess B. Antihypertensive therapy in diabetes mellitus. Ther Umsch. 1999;56:25-32.
91. Abbott KC, Bakris GL. Treatment of the diabetic patient: focus on cardiovascular and renal risk reduction. Prog Brain Res. 2002;139: 289-298.
92. Lovell HG. Angiotensin converting enzyme inhibitors in normotensive diabetic patients with microalbuminuria. Cochrane Database Syst Rev. 2001;1:CD002183.
93. Arcaro G, Zenere BM, Saggiani F, et al. ACE inhibitors improve endothelial function in type 1 diabetic patients with normal arterial pressure and microalbuminuria. Diabetes Care. 1999;22:1536-1542.
94. Parving HH, Hovind P. Microalbuminuria in type 1 and type 2 diabetes mellitus: evidence with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers for treating early and preventing clinical nephropathy. Curr Hypertens Rep. 2002;4:387-393.
95. Betteridge DJ. Diabetic dyslipidaemia. Diabetes Obes Metab 2000; 2(suppl 1):S31-S36.
96. Adeli K, Taghibiglou C, Van Iderstine SC, et al. Mechanisms of hepatic very low-density lipoprotein overproduction in insulin resistance. Trends Cardiovasc Med. 2001;11:170-176.
97. Castro Cabazas M, Halkes CJ, Erkelens DW. Obesity and free fatty acids: double trouble. Nutr Metab Cardiovasc Dis. 2001;11:134-142.
98. Mustad VA, Etherton TD, Cooper AD, et al. Reducing saturated fat intake is associated with increased levels of LDL receptors on mononuclear cells in healthy men and women. J Lipid Res. 1997;38:459-468.
99. Ginsberg HN. Lipoprotein physiology in nondiabetic and diabetic states. Relationship to atherogenesis. Diabetes Care. 1991;14:839-855.
100. Iuliano L. The oxidant stress hypothesis of atherogenesis. Lipids. 2001;36(suppl):S31-S34.
101. Erbey JR, Robbins D, Forrest KY, et al. Low-density lipoprotein particle size and coronary artery disease in a childhood-onset type 1 diabetes population. Metabolism. 1999;48:531-534.
102. Kreisberg RA. Diabetic dyslipidemia. Am J Cardiol. 1998;82:67U-73U.
103. Bhatnagar D. Should pediatric patients with hyperlipidemia receive drug therapy? Paediatr Drugs. 2002;4:223-230.
104. de Jongh S, Lilien MR, op't Roodt J, et al. Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol. 2002;40:2117-2121.
105. Athyros VG, Papageorgiou AA, Kontopoulos AG. Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis. 2002;163:205-206.
106. Lambert M, Lupien PJ, Gagne C, et al. Treatment of familial hypercholesterolemia in children and adolescents: effect of lovastatin. Canadian Lovastatin in Children Study Group. Pediatrics. 1996;97:619-628.
107. Stein EA, Illingworth DR, Kwiterovich PO Jr, et al. Efficacy and safety of lovastatin in adolescent males with heterozygous familial hypercholesterolemia: a randomized controlled trial. JAMA. 1999;281:137-144.
108. Scandinavian Simvastatin Survival Study Group. Randomized trial of cholesterol lowering in 4444 patients with coronary heart study: the Scandinavian Survival Study (4S). Lancet. 1994;344:1383.
109. Oida K. CARE: Cholesterol and Recurrent Events trial. Nippon Rinsho. 2001;59(suppl 3):427-432.
110. Farmer JA. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized, placebo-controlled trial. Curr Atheroscler Rep. 2003;5:93-94.
111. Hostetter AL. Screening for dyslipidemia. Practice parameter. Am J Clin Pathol. 1995;103:380-385.
112. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care. 1999;22:532.
113. Hirsch GA, Vaid N, Blumenthal RS. Perspectives: the significance of measuring non-HDL cholesterol. Prev Cardiol. 2002;5:156-159.
114. Lu W, Resnick HE, Jablonski KA, et al. Non-HDL cholesterol as a predictor of cardiovascular disease in type 2 diabetes: the Strong Heart Study. Diabetes Care. 2003;26:16-23.
115. Srinivasin SR, Meyers L, Berenson GS. Distribution and correlates of non-high-density lipoprotein cholesterol in children: the Bogalusa Heart Study. Pediatrics. 2002;110:e29.
116. Valente AM, Newburger JW, Lauer RM. Results of expert meetings: conducting pediatric cardiovascular trials. Hyperlipidemia in children and adolescents. Am Heart J. 2001;142:433-439.
117. Grundy SM. Approach to lipoprotein management in 2001 National Cholesterol Guidelines. Am J Cardiol. 2002;90:11I-21i.
118. Rapp RJ. Hypertriglyceridemia: a review beyond low-density lipoprotein. Cardiol Rev. 2002;10:163-172.
119. Rashid S, Uffelman KD, Lewis GF. The mechanism of HDL lowering in hypertriglyceridemic, insulin-resistant states. J Diabetes Complications. 2002;16:24-28.
120. Obarzanek E, Kimm SY, Barton BA, et al. Long-term safety and efficacy of a cholesterol-lowering diet in children with elevated low-density lipoprotein cholesterol: seven-year results of the Dietary Intervention Study in Children (DISC). Pediatrics. 2001;107:256-264.
121. Garg A. Management of dyslipidemia in IDDM patients. Diabetes Care. 1994;17:224-234.
122. Perez Jimenez F. The pharmacological treatment of hypercholesterolemia. Rev Esp Cardiol. 1995;48(suppl 5):31-38.
123. Auer J, Berent R, Weber T, et al. Clinical significance of pleiotropic effects fostatins: lipid reduction and beyond. Curr Med Chem. 2002; 9:1831-1850.
124. Kent SM, Flaherty PJ, Coyle LC, et al. Effect of atorvastatin and pravastatin on serum C-reactive protein. Am Heart J. 2003;145:E8.
125. Swiatkowska M, Pawlowska Z, Szzemraj J, et al. Cerivastatin, an HMG-CoA reductase inhibitor, reduces plasminogen activator inhibitor-1 (PAI-1) expression in endothelial cells by down-regulation of cellular signaling and the inhibition of PAI-1 promotor activity. Jpn J Pharmacol. 2002;90:337-344.
126. Hattori Y, Nakanishi N, Kasai K. Statin enhances cytokine-mediated induction of nitric oxide synthesis in vascular smooth muscle cells. Cardiovasc Res. 2002;54:649-658.
127. Comaschi MA, Menozzi F. Pravastatin and the development of diabetes mellitus. Evidence for a protective treatment in the West of Scotland Coronary Prevention Study. Ital Heart J. 2001;2(5 suppl):556-558.
128. Ezetimibe Study Group.Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002;90:1084-1091.
129. Farnier M. Ezetimibe in hypercholesterolemia. Int J Clin Pract. 2002; 56:611-614.
130. Gagne C, Gaudet D, Bruckert E. Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia. Circulation. 2002;105:2469-2475.
131. Ovalle F, Bell DS. Effect of thiazolidinediones on high-density lipoprotein subfractions. Endocr Pract. 2002;8:102-104.
132. Nass CM, Blumenthal RS. Glitazones and the potential improvement of lipid profiles in diabetes patients at high risk for cardiovascular disease. Am J Managed Care. 2000;6(24 suppl):S1247-S1256.
133. King AB, Armstrong DU. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review. Diabetes Technol Ther. 2002;4:145-151.
134. Gegick CG, Altheimer MD. Comparison of effects of thiazolidinediones on cardiovascular risk factors: observations from a clinical practice. Endocr Pract. 2001;7:162-169.
135. Bocher V, Chinetti G, Fruchart JC, et al. Role of the peroxisome proliferator-activated receptors (PPARS) in the regulation of lipids and inflammation control. J Soc Biol. 2002;196:47-52.
136. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes. 2002;51:2968-2974.